Long-term Survivorship Challenges of Advanced/Metastatic GIST Patients Responding to Tyrosine Kinase Inhibitor Treatment: an Observational Study

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Age 18 years or older (no upper age limit);
* Advanced or metastatic GIST, diagnosis of GIST must be histologically proven;
* Treated with TKIs (eg. sunitinib, regorafenib, avapritinib, ripretinib) for at least 2 years; TKI treatment ongoing; interruptions up to 3 months are allowed;
* Able to read and answer questionnaires;
* Able to provide informed consent.

Exclusion Criteria:

* Patients receiving TKI in an adjuvant treatment setting.
* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before inclusion the study.
* Patients who are too ill (death is imminent), as determined by the referring health care professional.